Antony Blanc Named CureVac’s Chief Business Officer and Chief Commercial Officer

CureVac has hired Antony Blanc as Chief Business Officer and Chief Commercial Officer, where he will lead the company’s partnerships, programs, and commercial initiatives. He was previously an Expert Associate Partner with McKinsey & Company, where he was focused on European biotechnology clients. He previously spent several years with GlaxoSmithKline, where he held various leadership roles, ultimately serving as Vice President of Global Integration Lead for the Novartis Vaccines business. He formerly held senior roles with Synosia Therapeutics, Syngenta and Syntem.

CureVac is a biopharmaceutical company, headquartered in Tübingen, Germany, that develops therapies based on messenger RNA (mRNA). The company’s focus is on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. CureVac currently employs about 500 people.